BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kupčová V, Fedelešová M, Bulas J, Kozmonová P, Turecký L. Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. Int J Environ Res Public Health 2019;16:E3570. [PMID: 31554274 DOI: 10.3390/ijerph16193570] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Gheorghe G, Bungău S, Ceobanu G, Ilie M, Bacalbaşa N, Bratu OG, Vesa CM, Găman MA, Diaconu CC. The non-invasive assessment of hepatic fibrosis. J Formos Med Assoc 2021;120:794-803. [PMID: 32861550 DOI: 10.1016/j.jfma.2020.08.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
2 Zhou W, Zhu Z, Xiao X, Li C, Zhang L, Dang Y, Ge G, Ji G, Zhu M, Xu H. Jiangzhi Granule attenuates non-alcoholic steatohepatitis by suppressing TNF/NFκB signaling pathway-a study based on network pharmacology. Biomed Pharmacother 2021;143:112181. [PMID: 34649337 DOI: 10.1016/j.biopha.2021.112181] [Reference Citation Analysis]
3 Xia SJ, Tang LZ, Li WH, Xu ZS, Zhang LL, Cheng FG, Chen HX, Wang ZH, Luo YC, Dai AN, Fan JG. Serum syndecan-4 is associated with nonalcoholic fatty liver disease. J Dig Dis 2021. [PMID: 34374198 DOI: 10.1111/1751-2980.13037] [Reference Citation Analysis]
4 Kim KM, Roh JH, Lee S, Yoon JH. Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease. Sci Rep 2021;11:2884. [PMID: 33536442 DOI: 10.1038/s41598-021-81959-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Karrar A, Rajput B, Hariharan S, Abdelatif D, Houry M, Moosvi A, Ali I, Tan D, Noor S, Esmaeili D, Felix S, Alaparthi L, Otgonsuren M, Lam B, Goodman ZD, Younossi ZM. Major Histocompatibility Complex Class I-Related Chain A Alleles and Histology of Nonalcoholic Fatty Liver Disease. Hepatol Commun 2021;5:63-73. [PMID: 33437901 DOI: 10.1002/hep4.1610] [Reference Citation Analysis]
6 Lira MMP, de Medeiros Filho JEM, Baccin Martins VJ, da Silva G, de Oliveira Junior FA, de Almeida Filho ÉJB, Silva AS, Henrique da Costa-Silva J, de Brito Alves JL. Association of worsening of nonalcoholic fatty liver disease with cardiometabolic function and intestinal bacterial overgrowth: A cross-sectional study. PLoS One 2020;15:e0237360. [PMID: 32845887 DOI: 10.1371/journal.pone.0237360] [Reference Citation Analysis]
7 Aggarwal P, Noureddin M, Harrison S, Jeannin S, Alkhouri N. Nonalcoholic steatohepatitis (NASH) cirrhosis: A snapshot of therapeutic agents in clinical development and the optimal design for clinical trials. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2032640] [Reference Citation Analysis]
8 Kim MN, Han K, Yoo J, Ha Y, Chon YE, Lee JH, Simon TG, Chan AT, Hwang SG. Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Sci Rep 2021;11:9154. [PMID: 33911167 DOI: 10.1038/s41598-021-88733-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Pan X, Xie X, Peng H, Cai X, Li H, Hong Q, Wu Y, Lin X, Xu S, Peng XE. Risk Prediction for Non-alcoholic Fatty Liver Disease Based on Biochemical and Dietary Variables in a Chinese Han Population. Front Public Health 2020;8:220. [PMID: 32714888 DOI: 10.3389/fpubh.2020.00220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Huard K, Smith AC, Cappon G, Dow RL, Edmonds DJ, El-Kattan A, Esler WP, Fernando DP, Griffith DA, Kalgutkar AS, Ross TT, Bagley SW, Beebe D, Bi YA, Cabral S, Crowley C, Doran SD, Dowling MS, Liras S, Mascitti V, Niosi M, Pfefferkorn JA, Polivkova J, Préville C, Price DA, Shavnya A, Shirai N, Smith AH, Southers JR, Tess DA, Thuma BA, Varma MV, Yang X. Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting. J Med Chem 2020;63:10879-96. [PMID: 32809824 DOI: 10.1021/acs.jmedchem.0c00640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Perez-Diaz-Del-Campo N, Riezu-Boj JI, Marin-Alejandre BA, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Milagro FI, Tur JA, Abete I, Zulet MA, Martinez JA. Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study. Diagnostics (Basel) 2021;11:1083. [PMID: 34199237 DOI: 10.3390/diagnostics11061083] [Reference Citation Analysis]
12 Vancells Lujan P, Viñas Esmel E, Sacanella Meseguer E. Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients 2021;13:1442. [PMID: 33923255 DOI: 10.3390/nu13051442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]